FIELD: biotechnology.
SUBSTANCE: invention relates to fusion proteins SIRPalpha-4-1BBL, and can be used in medicine for treating cancer, whose cells express CD47. Fusion protein SIRPalpha-4-1BBL is constructed in the form of a homotrimer, containing at its N-end the amino acid sequence of signal regulatory protein alpha (SIRPalpha), and at its C-end amino acid sequence of ligand 4-1BB (4-1BBL), connected by means of linker from one glycine. Invention enables to obtain a fusion protein which is capable of binding CD47 and 4-1BB, activating 4-1BB signaling pathway in a cell expressing said 4-1BB, co-stimulation of immune cells expressing said 4-1BB, and intensified phagocytosis of pathological cells expressing said CD47 by phagocytes as compared to that in the absence of said fusion protein SIRPalpha-4-1BBL.
EFFECT: fusion protein SIRPα-4-1bbl and methods of using it are proposed.
17 cl, 15 dwg, 1 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| EMBODIMENTS OF SIRP-ALPHA-4-1BBL FUSION PROTEIN AND METHODS OF USE THEREOF | 2019 |
|
RU2815515C2 |
| PD1-4-1BBL FUSION PROTEIN AND METHODS OF ITS USE | 2018 |
|
RU2769513C2 |
| IMMUNOMODULATORY FUSED PROTEINS AND THEIR APPLICATION METHODS | 2016 |
|
RU2755227C2 |
| BINDING OF FUSED PROTEIN TO CD47 PROTEIN AND ITS USE | 2019 |
|
RU2787521C2 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
| CHIMERIC PROTEINS BASED ON TIGIT AND LIGHT | 2018 |
|
RU2775490C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| ANTIBODY AGAINST SIRPα | 2019 |
|
RU2791002C2 |
